The trial is designed to assess the tolerability, efficacy, and safety of two different dosages of the therapy.

Oculis Holding ( (OCS) ) has issued an update. Oculis Holding has announced positive results from a Phase 2 trial for OCS-05, a potential first-in-class neuroprotective therapy for acute optic ...

By Karen Roman Oculis Holding AG (Nasdaq: OCS) said Phase 2 of its neuroprotective candidate OCS-05 met key endpoints of ...

The trial met safety and efficacy endpoints. OCS-05 met safety and efficacy endpoints in the treatment of acute optic neuritis in a phase 2 trial, according to a press release from Oculis.

Oculis’ peptidomimetic small molecule has been shown to help protect the eyes of patients with inflammation of the optic ...

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in ...

BofA raised the firm’s price target on Oculis (OCS) to $31 from $23 and keeps a Buy rating on the shares. The company reported Phase 2 results ...

One of the more obvious first signs of MS is a problem with vision, known as optic neuritis where swelling damages the optic ...

Numbness and tingling are also common initial symptoms of MS, according to the NHS. These abnormal sensations can often ...

Oculis (NASDAQ:OCS – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued to ...

When the body’s immune system reacts to an infection like HMPV, it can sometimes overreact, causing inflammation not only in ...